天津力生制药股份有限公司 关于2024年限制性股票预留部分授予登记完成的公告

Core Viewpoint - The company has announced the details of its 2024 restricted stock incentive plan, including the grant date, number of shares, and pricing, which aims to motivate and retain key personnel through equity incentives [2][4][7]. Group 1: Incentive Plan Details - The grant date for the restricted stock is set for December 5, 2025, with the registration completion date on January 9, 2026 [2][22]. - A total of 740,000 shares will be granted, representing 0.2872% of the company's total share capital prior to the grant [2][7]. - The grant price for the restricted stock is set at 10.24 yuan per share [2][7]. Group 2: Approval Process - The company held several meetings to approve the incentive plan, including the seventh board meeting on December 20, 2024, and the first extraordinary general meeting of shareholders on February 5, 2025 [3][4][5]. - The plan has undergone verification by the supervisory board and independent financial advisors, ensuring compliance with relevant regulations [3][5][7]. Group 3: Stock Repurchase and Impact - The restricted stock is sourced from shares repurchased from the secondary market, with a total of 7,209,980 shares repurchased, accounting for 2.80% of the company's total share capital [25][24]. - The stock repurchase was conducted at prices ranging from 17.28 yuan to 18.50 yuan per share, with a total expenditure of approximately 129.41 million yuan [25]. Group 4: Performance Assessment and Conditions - The incentive plan includes performance assessment criteria that must be met for the release of the restricted stock, with evaluations conducted annually over three accounting years [15][19]. - Individual performance assessments will be tailored to different roles, with a grading system to determine eligibility for stock release [19][20]. Group 5: Financial Implications - The issuance of restricted stock will not change the total share capital, thus not affecting the earnings per share [23]. - The company will account for the costs associated with the restricted stock in accordance with relevant accounting standards, adjusting for the number of shares eligible for release based on performance metrics [24][25].